Healthcare
Cytokinetics Inc(CYTK)
Live Price
Offline$78.78
+0.86% today
1Y Change
+137.93%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $9.49B
- Revenue Growth
- +376.6%
- EPS Growth
- -24.3%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Cytokinetics Inc (CYTK) is a Healthcare stock with a market cap of $9.49B and listed on NASDAQ. The stock last traded around $78.78 and up 137.9% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +376.6%, EPS growth of -24.3%, a dividend yield of 0.0%. What stands out right now is revenue +376.6%, EPS -24.3%, free cash flow -33.8% with operating margin -605.1% and ROIC -56.2%. Valuation already assumes a fairly strong business story at price/sales 89.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines CYTK price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+376.6% vs +7.6% peer median
Operating Margin
Below sector median
-605.1% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +376.6% and EPS is at -24.3%, with operating margin around -605.1%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -1.6% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 5, 2026 | โ | -2.9% | -3.0% | -8.3% |
2026 Feb 24, 2026 | -1.4% | -10.3% | -13.4% | -14.4% |
2025 Nov 5, 2025 | +3.1% | +1.9% | +11.4% | +12.4% |
Benchmark Edge
CYTK vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CYTK
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CYTK Max Drawdown
-15.01%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CYTK and SPY.
Company Overview
Cytokinetics Inc
NASDAQ
Cytokinetics, Incorporated is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors. These small-molecule therapies target debilitating diseases where muscle performance is compromised or declining, including amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, hypertrophic cardiomyopathy, and chronic obstructive pulmonary disease. By specifically engineering compounds to enhance muscle function and contractility, Cytokinetics addresses impaired muscle function in cardiovascular and neuromuscular conditions. The company advances muscle-directed investigational medicines aimed at improving health outcomes for patients with serious diseases of cardiac and skeletal muscle dysfunction. Founded in 1997 and headquartered in South San Francisco, California, Cytokinetics leverages expertise in muscle biology to build a pipeline of sarcomere-directed therapies, positioning it as a key player in specialized biopharmaceutical innovation for muscle-related disorders.
- Leadership
- Mr. Robert I. Blum
- Employees
- 673
- Street Address
- 350 Oyster Point Boulevard
- Mailing
- South San Francisco, CA, 94080
- Region
- South San Francisco, CA, United States
- Last Updated
- May 11, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 89.7
- Price/Book
- โ
Growth
- Revenue
- +376.6%
- EPS
- -24.3%
- Free Cash Flow
- -33.8%
Profitability
- Gross Margin
- 90.3%
- Operating Margin
- -605.1%
- Net Margin
- -784.0%
- ROE
- 139.7%
- ROIC
- -56.2%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 4.21
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.